Boehringer Ingelheim selects nanobody for development of Alzheimer's treatment
Ingelheim/Ghent - Boehringer Ingelheim has selected an antibody candidate from its $265 million worldwide research programme, resulting from the Alzheimer's research collaboration with Belgian Ablynx NV, signed in January 2007. Boehringer paid a EUR 2million milestone to the developer of single chain camelidae nanobodies and will be solely responsible for the development, manufacture and commercialization of the drug candidate. Nanobodies have a high homology with the VH domains of human antibodies and can be further humanized without loss of activity, according to the Belgian drugmaker. The nanobdy candidate targets a worldwide 30 million people market that is predicted to grow in the future.